As a result, GPR119 it has become an emerging target for treatment of type 2 diabetes, and its agonist is expected to be a new type of hypoglycemic for treatment of type 2 diabetes (Li et al., 2021). This evidence concerns the gene GPR119 and type 2 diabetes mellitus.